S trobilurin类杀菌剂是在具有杀菌活性的天然β-甲氧基丙烯酸酯衍生物的基础上研发出来的,具有广谱、高效、安全的特点。主要以粘噻唑为例综述了该类杀菌剂作用靶标及作用位点的研究过程及最新进展。生化作用机理的研究明确了粘噻唑作...S trobilurin类杀菌剂是在具有杀菌活性的天然β-甲氧基丙烯酸酯衍生物的基础上研发出来的,具有广谱、高效、安全的特点。主要以粘噻唑为例综述了该类杀菌剂作用靶标及作用位点的研究过程及最新进展。生化作用机理的研究明确了粘噻唑作用于线粒体呼吸链bc1复合物中的细胞色素b及铁硫蛋白,阻止了从细胞色素b到细胞色素c1的电子传递,从而抑制线粒体的呼吸作用;蛋白质晶体学研究明确了粘噻唑的作用位点(Qo位点)是通过氢键与铁硫蛋白及细胞色素b的残基结合的。其他strobilurin类杀菌剂和粘噻唑具有相同的靶标,但由于各化合物之间存在一定的结构差异,其具体作用位点亦有一定的差别。展开更多
抗体偶联药物(antibody drug conjugates,ADCs)是通过化学键将毒性小分子与单克隆抗体偶联的靶向抗肿瘤药物,其充分利用了抗体的特异性和毒性小分子的高抗肿瘤活性,达到了高效低毒的目的。抗体、连接物以及毒性小分子是ADCs的3个重要组...抗体偶联药物(antibody drug conjugates,ADCs)是通过化学键将毒性小分子与单克隆抗体偶联的靶向抗肿瘤药物,其充分利用了抗体的特异性和毒性小分子的高抗肿瘤活性,达到了高效低毒的目的。抗体、连接物以及毒性小分子是ADCs的3个重要组成部分,文章介绍了ADCs制备中靶点选择,抗体小型化和人源化改造,高活性毒性小分子使用,可断开和不可断开连接物的特点以及越来越受关注的定点偶联策略,为ADCs临床前研发提供依据。展开更多
A highly effective medicine is urgently required to cure coronavirus disease 2019(COVID-19).For the purpose,we developed a molecular docking based webserver,namely D3 Targets-2019-nCoV,with two functions,one is for pr...A highly effective medicine is urgently required to cure coronavirus disease 2019(COVID-19).For the purpose,we developed a molecular docking based webserver,namely D3 Targets-2019-nCoV,with two functions,one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies,the other is for identifying lead compounds against potential drug targets via docking.This server has its unique features,(1)the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible;(2)all the potential ligand-binding sites with volume larger than 200 A^3 on a protein structure were identified for docking;(3)correlation information among some conformations or binding sites was annotated;(4)it is easy to be updated,and is accessible freely to public(https://www.d3 pharma.com/D3 Targets-2019-nCoV/index.php).Currently,the webserver contains 42 proteins[20 severe acute respiratory syndrome-related coronavirus 2(SARS-CoV-2)encoded proteins and 22 human proteins involved in virus infection,replication and release]with 69 different conformations/structures and 557 potential ligand-binding pockets in total.With 6 examples,we demonstrated that the webserver should be useful to medicinal chemists,pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19.展开更多
文摘抗体偶联药物(antibody drug conjugates,ADCs)是通过化学键将毒性小分子与单克隆抗体偶联的靶向抗肿瘤药物,其充分利用了抗体的特异性和毒性小分子的高抗肿瘤活性,达到了高效低毒的目的。抗体、连接物以及毒性小分子是ADCs的3个重要组成部分,文章介绍了ADCs制备中靶点选择,抗体小型化和人源化改造,高活性毒性小分子使用,可断开和不可断开连接物的特点以及越来越受关注的定点偶联策略,为ADCs临床前研发提供依据。
基金supported by the National Key Research and Development Program of China(2017YFB0202601 and 2016YFA0502301)
文摘A highly effective medicine is urgently required to cure coronavirus disease 2019(COVID-19).For the purpose,we developed a molecular docking based webserver,namely D3 Targets-2019-nCoV,with two functions,one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies,the other is for identifying lead compounds against potential drug targets via docking.This server has its unique features,(1)the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible;(2)all the potential ligand-binding sites with volume larger than 200 A^3 on a protein structure were identified for docking;(3)correlation information among some conformations or binding sites was annotated;(4)it is easy to be updated,and is accessible freely to public(https://www.d3 pharma.com/D3 Targets-2019-nCoV/index.php).Currently,the webserver contains 42 proteins[20 severe acute respiratory syndrome-related coronavirus 2(SARS-CoV-2)encoded proteins and 22 human proteins involved in virus infection,replication and release]with 69 different conformations/structures and 557 potential ligand-binding pockets in total.With 6 examples,we demonstrated that the webserver should be useful to medicinal chemists,pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19.
